The annual global economic burden of heart failure
Introduction
In nearly all regions of the world HF is both common and increasing [1], [2]. Although death rates from cardiovascular disease (CVD) as a whole have declined, HF is the only major CVD whose prevalence and incidence are thought to be increasing [3] and the long-term prognosis associated with HF is poor [4].
As the global problem of HF increases, there is also the significant economic burden of disease to be considered. It is increasingly important for governments and health organizations to have an estimate of the costs attributed to HF, as they will have to plan, predict and finance the care of a rapidly growing and aging global population.
The economic impact of a disease is considered in terms of direct and indirect costs. Direct costs include healthcare expenditure on hospital services, medications, physician costs, primary healthcare costs and follow-up. Indirect costs include healthcare expenditure in terms of lost productivity resulting from morbidity and mortality, sickness benefit and welfare support.
Although some data on the prevalence and cost of HF exists, this is scarce and largely limited to the high-income countries of Western Europe and North America. There is almost a complete lack of data regarding middle to low-income countries, despite the fact they represent over 80% of the world's population.
The objective of this study was to calculate, from available information, a best estimate of the overall cost of HF per annum, in both direct and indirect terms, across the globe.
Section snippets
Direct and indirect HF costs sources
A literature review of studies assessing the crude prevalence rates and economic burden of HF was performed using the MEDLINE database. The terms heart failure, myocardial failure, congestive heart failure and medical subject headings economics, statistics and numerical data were used and abstracts reviewed for relevance (Fig. 1).
In addition, data from government department of health documents, professional society reports and non-profit organization reports were included and referenced
Statistics
Where relevant, comparisons between mean values of groups were made using the Student paired t test. A p value < 0.05 was pre-defined as statistically significant.
Data sources
13 published economic estimates of healthcare costs attributed specifically to HF were included in the study. Only 1 source (American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart Disease and Stroke Statistics Report, 2013) included indirect HF costs [9] (Table 1). Study estimates spanned a range of 22 years. The earliest economic estimate was from 1990 and the latest 2012.
Published economic estimates were predominantly from the USA, Europe and Australasia, with
Discussion
HF is a common problem, affecting between 1–2% of the population [16]. It represents a growing global health problem that will reach epidemic proportions in an ageing and rapidly expanding global population. Currently, the crude prevalence rate of HF in high-income countries is greater than in the economically developing world [9], [16], [21], [22], [23], [24], [25], [26], though reporting bias may contribute to this. In high-income countries HF is most commonly the consequence of a composite
Study limitations
Despite efforts made to utilize the available published data resourcefully, there are limitations in this study. Fundamentally, the values provided are only estimates of economic burden based on best available information. The existing published economic dataset has very limited global representation with a heavy bias towards data from high-income countries. In particular, no economic HF data exists in WDI defined low-income countries, and so middle and low-income countries have been
Conclusions
This study defines the global economic impact of HF. It provides a benchmark value intended to develop understanding of the impact of HF outside of the conventional framework of mortality and morbidity.
It provides new information, especially relevant in a rapidly changing global economic landscape, highlighting the burden of disease in middle and low-income countries. For the first time it provides economic estimates aimed at these regions, where epidemiological and economic data currently do
References (45)
- et al.
The epidemiological features of heart failure in developing countries: a review of the literature
Int J Cardiol
(2001 Sep) - et al.
Cost-effectiveness of specialized multidisciplinary heart failure clinics in Ontario
Can Value Health
(2010 Dec) - et al.
A new look at adult chronic heart failure in Africa in the age of the Doppler echocardiography: experience of the medicine department at Yaounde General Hospital
Ann Cardiol Angeiol (Paris)
(2005) - et al.
Epidemiology, aetiology, and prognosis of heart failure
Heart
(2000 May 1) - et al.
Dying from heart failure: lessons from palliative care
BMJ
(1998 Oct 10) - et al.
Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the medicare population
Arch Intern Med
(1999 Mar 8) Data retrieved December 1, 2012, from National Health Account database
Data retrieved December 1, 2012, from World DataBank database. World Development Indicators
Data retrieved December 1, 2012, from World DataBank database. World Bank national accounts data, and OECD National Accounts data files
Data retrieved December 1, 2012, from World DataBank database. United Nations Population Division. World Population Prospects, (2) United Nations Statistical Division. Population and Vital Statistics Report (various years), (3) Census reports and other statistical publications from national statistical offices, (4) Eurostat: Demographic Statistics, (5) Secretariat of the Pacific Community: Statistics and Demography Programme, and (6) U.S. Census Bureau: International Database
Heart disease and stroke statistics—2013 update: a report from the American Heart Association
Circulation
Heart failure: the commonest reason for hospital admission in Germany
Dtsch Arztebl Int
The current cost of heart failure to the National Health Service in the UK
Eur J Heart Fail
What is the current scenario for heart failure in Brazil?
Arq Bras Cardiol
Cost of heart failure in Swedish primary healthcare
Scand J Prim Health Care
Costs of chronic heart failure in Spain
An Med Interna
Economics of chronic heart failure
Eur J Heart Fail
The costs of heart failure in Poland from the public payer's perspective. Polish programme assessing diagnostic procedures, treatment and costs in patients with heart failure in randomly selected outpatient clinics and hospitals at different levels of car. Kardiologia Polska
Pol Heart J
Health system costs of cardiovascular diseases and diabetes in Australia 1993–94. Health and welfare expenditure series no. 5. Cat. no. HWE 11
Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study
BMJ
Impact of heart failure on hospital activity and healthcare costs in Belgium
J Med Econ
Data retrieved December 1, 2012, from National Health Survey: Summary of results. 436 4.0. 2004–05
Cited by (639)
Effects of childhood obesity on heart failure and its associated risk factors in the European population: A Mendelian randomization study
2024, Nutrition, Metabolism and Cardiovascular DiseasesExercise-based cardiac rehabilitation for left ventricular function in patients with heart failure: A systematic review and meta-analysis
2024, Current Problems in CardiologyOverview article: Impact of primary and secondary care collaboration on hospitalization for chronic heart failure: Two comparative studies
2023, Zeitschrift fur Evidenz, Fortbildung und Qualitat im GesundheitswesenThe effects on rehospitalization rate of transitional care using information communication technology in patients with heart failure: A scoping review
2023, International Journal of Nursing Studies AdvancesThe impact of platelet-to-lymphocyte ratio on clinical outcomes in heart failure: a systematic review and meta-analysis
2024, Therapeutic Advances in Cardiovascular Disease